A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

Effective start/end date26/07/2125/07/26


  • phase 2 study
  • treatment efficacy
  • treatment safety
  • head and neck cancer